JP2022111148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022111148A5 JP2022111148A5 JP2022084854A JP2022084854A JP2022111148A5 JP 2022111148 A5 JP2022111148 A5 JP 2022111148A5 JP 2022084854 A JP2022084854 A JP 2022084854A JP 2022084854 A JP2022084854 A JP 2022084854A JP 2022111148 A5 JP2022111148 A5 JP 2022111148A5
- Authority
- JP
- Japan
- Prior art keywords
- icos
- bispecific antibody
- monomer
- antibody
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381239P | 2016-08-30 | 2016-08-30 | |
| US62/381,239 | 2016-08-30 | ||
| US201762456033P | 2017-02-07 | 2017-02-07 | |
| US62/456,033 | 2017-02-07 | ||
| US201762479723P | 2017-03-31 | 2017-03-31 | |
| US62/479,723 | 2017-03-31 | ||
| US15/623,314 US10787518B2 (en) | 2016-06-14 | 2017-06-14 | Bispecific checkpoint inhibitor antibodies |
| US15/623,314 | 2017-06-14 | ||
| JP2019511464A JP7080219B2 (ja) | 2016-08-30 | 2017-08-30 | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 |
| PCT/US2017/049497 WO2018045110A1 (en) | 2016-08-30 | 2017-08-30 | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511464A Division JP7080219B2 (ja) | 2016-08-30 | 2017-08-30 | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022111148A JP2022111148A (ja) | 2022-07-29 |
| JP2022111148A5 true JP2022111148A5 (https=) | 2023-02-20 |
Family
ID=65632988
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511464A Active JP7080219B2 (ja) | 2016-08-30 | 2017-08-30 | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 |
| JP2022084854A Pending JP2022111148A (ja) | 2016-08-30 | 2022-05-24 | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511464A Active JP7080219B2 (ja) | 2016-08-30 | 2017-08-30 | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3507306B1 (https=) |
| JP (2) | JP7080219B2 (https=) |
| KR (2) | KR20230130174A (https=) |
| CN (1) | CN110267990B (https=) |
| AU (1) | AU2017321625A1 (https=) |
| CA (1) | CA3035343A1 (https=) |
| DK (1) | DK3507306T3 (https=) |
| HR (1) | HRP20251424T1 (https=) |
| IL (1) | IL265046B2 (https=) |
| MX (1) | MX2023006786A (https=) |
| SG (1) | SG11201901712YA (https=) |
| ZA (1) | ZA201901752B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2915378T3 (es) * | 2013-09-13 | 2022-06-22 | Hoffmann La Roche | Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares |
| KR102170077B1 (ko) * | 2018-05-21 | 2020-10-27 | 인하대학교 산학협력단 | Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도 |
| KR102521276B1 (ko) * | 2018-10-31 | 2023-04-12 | 바이오아트라, 인코퍼레이티드 | 항-ctla4 항체, 항체 단편, 이들의 면역접합체 및 그 용도 |
| AU2021256652A1 (en) * | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies |
| AU2021257570A1 (en) * | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
| CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
| KR102911451B1 (ko) * | 2022-05-24 | 2026-01-09 | 건국대학교 글로컬산학협력단 | Rps3 결합 단클론 항체 및 이의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546543B2 (en) * | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| AU2009333580B2 (en) * | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2638072A4 (en) * | 2010-11-12 | 2014-05-07 | Univ Rockefeller | FUSION PROTEINS FOR HIV THERAPY |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CA2898100C (en) * | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| CA2902739C (en) * | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| BR112016015140A2 (pt) * | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| JP6668345B2 (ja) * | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| BR112017011166A2 (pt) * | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| EP3623386B1 (en) * | 2015-01-08 | 2022-04-13 | BioNTech SE | Agonistic tnf receptor binding agents |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
-
2017
- 2017-08-30 AU AU2017321625A patent/AU2017321625A1/en not_active Abandoned
- 2017-08-30 JP JP2019511464A patent/JP7080219B2/ja active Active
- 2017-08-30 EP EP17765002.5A patent/EP3507306B1/en active Active
- 2017-08-30 HR HRP20251424TT patent/HRP20251424T1/hr unknown
- 2017-08-30 DK DK17765002.5T patent/DK3507306T3/da active
- 2017-08-30 CA CA3035343A patent/CA3035343A1/en active Pending
- 2017-08-30 IL IL265046A patent/IL265046B2/en unknown
- 2017-08-30 KR KR1020237029969A patent/KR20230130174A/ko not_active Ceased
- 2017-08-30 CN CN201780060900.7A patent/CN110267990B/zh active Active
- 2017-08-30 SG SG11201901712YA patent/SG11201901712YA/en unknown
- 2017-08-30 KR KR1020197009280A patent/KR102575681B1/ko active Active
-
2019
- 2019-02-27 MX MX2023006786A patent/MX2023006786A/es unknown
- 2019-03-20 ZA ZA2019/01752A patent/ZA201901752B/en unknown
-
2022
- 2022-05-24 JP JP2022084854A patent/JP2022111148A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022111148A5 (https=) | ||
| JP2019513009A5 (https=) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2018516554A5 (https=) | ||
| JP2019525738A5 (https=) | ||
| JP2019518721A5 (https=) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2019513370A5 (https=) | ||
| JP2021501162A5 (https=) | ||
| IL263542B2 (en) | Bispecific antibodies inhibit immunological checkpoint | |
| JP2019532017A5 (https=) | ||
| AR126758A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| JP2018508483A5 (https=) | ||
| IL265541B1 (en) | Bispecific antibodies and compositions comprising thereof for treating cancer | |
| RU2018107658A (ru) | Новые антитела против pd-l1 | |
| JP2024023228A5 (https=) | ||
| JP2015163068A5 (https=) | ||
| JP2024086870A5 (https=) | ||
| JP2025118688A5 (https=) | ||
| JPWO2020076992A5 (https=) | ||
| JP2016529213A5 (https=) | ||
| JP2026026084A5 (https=) | ||
| JPWO2021127184A5 (https=) | ||
| JPWO2020028428A5 (https=) | ||
| JP2021514369A5 (https=) |